Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Dose-intensive chemotherapy with continuous infusion 5-fluorouracil].

T Tichler1, E Ghodsizade, A Katz

  • 1Sheba Medical Center, Tel Hashomer.

Harefuah
|June 23, 2001
PubMed
Summary

Continuous infusion of 5-fluorouracil (5FU) showed a 37% response rate in advanced cancers. This chemotherapy regimen demonstrated acceptable toxicity, supporting further clinical investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel retro-inverso gonadotropin-releasing hormone (GnRH) immunogen elicits antibodies that neutralize the activity of native GnRH.

Endocrinology·2003
Same author

Noninvasive native fluorescence imaging of head and neck tumors.

Technology in cancer research & treatment·2003
Same author

Variation in the DCP1 gene, encoding the angiotensin converting enzyme ACE, is not associated with increased susceptibility to Alzheimer's disease.

Psychiatric genetics·2003
Same author

Therapeutic potential of curcumin in human prostate cancer-I. curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells.

Prostate cancer and prostatic diseases·2002
Same author

Interpretation of spring recession curves.

Ground water·2002
Same author

Ideal vitamin C intake.

BioFactors (Oxford, England)·2002

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced malignancies often become refractory to conventional chemotherapy.
  • Exploring novel drug delivery methods and combinations is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of continuous infusion 5-fluorouracil (5FU) in patients with chemotherapy-refractory advanced malignancy.
  • To assess the safety profile of this dose-intensive program.

Main Methods:

  • A study involving 54 patients with advanced malignancy.
  • Administration of continuous infusion 5-fluorouracil (5FU) over 3 weeks, often in combination with other agents.
  • Reporting on the first 156 treatment courses.

Main Results:

Related Experiment Videos

  • A 37% overall response rate (19 out of 54 patients) was observed.
  • Complete response was achieved in 6% of patients (3 out of 54).
  • Toxicity was deemed acceptable, with mucositis reported in 26% and grade II-III toxicity in 6% of patients.

    • Conclusions:

    • Continuous infusion 5FU demonstrates promising efficacy in advanced, refractory cancers.
    • The observed toxicity profile is manageable and supports further investigation.
    • This dose-intensive program warrants continued study in disease-oriented clinical trials.